Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers

Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers

Epithelial Ovarian Cancer (EOC) is a leading cause of cancer-related deaths among women, mainly due to a lack of early detection and screening methods. Advanced immunoassay techniques, such as Luminex and proximity extension assay (PEA) technology, show promise in improving EOC detection by utilizin...

Full description

Bibliographic Details
Main Authors:	Vikneswary Ravi Kumar, Nirmala Chandralega Kampan, Nor Haslinda Abd Aziz, Chew Kah Teik, Mohamad Nasir Shafiee, P. Susthitha Menon
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	Cancers
Subjects:	epithelial ovarian cancer (EOC) biomarkers cancer antigen 125 (CA125) human epididymis protein 4 (HE4) immunoassay multiplex
Online Access:	https://www.mdpi.com/2072-6694/15/23/5607

Similar Items

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study
by: Manon Degez, et al.
Published: (2021-07-01)

Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance
by: Yi-Chao Lee, et al.
Published: (2015-11-01)

Performance of the IOTA ADNEX model combined with HE4 for identifying early-stage ovarian cancer
by: Suying Yang, et al.
Published: (2022-09-01)

Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case–control study
by: Kazimierz Pitynski, et al.
Published: (2015-12-01)

Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass
by: Reid Shaw, et al.
Published: (2022-03-01)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
by: Vincent Dochez, et al.
Published: (2019-03-01)

HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
by: Elena Ioana Braicu, et al.
Published: (2022-07-01)

Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer
by: Nabil Abdalla, et al.
Published: (2016-11-01)

Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
by: Ankita Sethi, et al.
Published: (2022-04-01)

Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
by: Aleksandra Gentry-Maharaj, et al.
Published: (2020-07-01)

The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses
by: Zehra Nihal Dolgun, et al.
Published: (2017-04-01)

Use of Sensor Array Analysis to Detect Ovarian Cancer through Breath, Urine, and Blood: A Case-Control Study
by: Roberto Angioli, et al.
Published: (2024-03-01)

Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer
by: Kelechi Njoku, et al.
Published: (2022-07-01)

Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?
by: Aneta Cymbaluk-Płoska, et al.
Published: (2021-03-01)

The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus
by: Anna Jagodzińska, et al.
Published: (2023-01-01)

HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect
by: Duanyang Liu, et al.
Published: (2018-06-01)

Correlation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital
by: Fatemeh Cheraghi, et al.
Published: (2020-01-01)

Role of HE4 and ROMA Score in Diagnosis of Ovarian Cancer in Egyptian Women
by: Nahla El-Attar, et al.
Published: (2021-01-01)

Biomarkers towards Ovarian Cancer Diagnostics: Present and Future Prospects
by: Meenal Rastogi, et al.

Meigs’ syndrome with elevated CA-125 and HE-4: a case of luteinized fibrothecoma
by: Jaroslaw Danilos, et al.
Published: (2015-06-01)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
by: Zheng Li-e, et al.
Published: (2016-01-01)

Molecular Biomarkers for the Early Detection of Ovarian Cancer
by: Ruiqian Zhang, et al.
Published: (2022-10-01)

Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features
by: Chloe E. Barr, et al.
Published: (2022-11-01)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
by: Chloe E. Barr, et al.
Published: (2023-02-01)

A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases
by: Beata Szymanska, et al.
Published: (2023-02-01)

Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy
by: Marcin Opławski, et al.
Published: (2022-08-01)

Current clinical application of serum biomarkers to detect and monitor ovarian cancer – update
by: Łukasz Janas, et al.
Published: (2022-01-01)

Evaluation of Human Epididymis Protein 4, Risk of Ovarian Malignancy Algorithm, and Risk of Malignancy Index Efficiency for Ameliorating Sensitivity and Specificity for Differentiating Benign from Malignant Adnexal Masses
by: Sonia Chawla, et al.

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
by: Elham Saffarieh, et al.
Published: (2022-08-01)

4-H Energy Encounters Leader's Guide
by: Linda Barber, et al.
Published: (2002-11-01)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
by: Jorge A. Alegría-Baños, et al.
Published: (2021-07-01)

Cancer Marker Immunosensing through Surface-Enhanced Photoluminescence on Nanostructured Silver Substrates
by: Georgia Geka, et al.
Published: (2023-12-01)

Immunosensing Cancer Markers through Surface-Enhanced Photoluminescence on Nanostructured Silver Substrates
by: Georgia Geka, et al.
Published: (2023-05-01)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
by: Chloe E. Barr, et al.
Published: (2022-04-01)

Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer
by: Masaya Uno, et al.
Published: (2023-07-01)

Biomarkers for Early Detection of Ovarian Cancer: A Review
by: Devarajappa Gari Bindu, et al.
Published: (2024-01-01)

Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
by: Yan Rong, et al.
Published: (2021-01-01)

Utility of Pelvic MRI and Tumor Markers HE4 and CA125 to Predict Depth of Myometrial Invasion and Cervical Involvement in Endometrial Cancer
by: Narges Zamani, et al.
Published: (2016-04-01)

HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial
by: Michel Fabbro, et al.
Published: (2024-01-01)

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
by: Miguel Ángel Elorriaga, et al.
Published: (2021-10-01)